nodes	percent_of_prediction	percent_of_DWPC	metapath
Phylloquinone—BGLAP—skeletal joint—psoriasis	0.169	0.524	CbGeAlD
Phylloquinone—BGLAP—vertebral column—psoriasis	0.134	0.417	CbGeAlD
Phylloquinone—Scleroderma—Acitretin—psoriasis	0.0519	0.0882	CcSEcCtD
Phylloquinone—Atrophy—Clobetasol propionate—psoriasis	0.0382	0.0649	CcSEcCtD
Phylloquinone—Atrophy—Fluocinonide—psoriasis	0.0344	0.0585	CcSEcCtD
Phylloquinone—BGLAP—Validated transcriptional targets of AP1 family members Fra1 and Fra2—IVL—psoriasis	0.0281	0.314	CbGpPWpGaD
Phylloquinone—GGCX—tendon—psoriasis	0.019	0.0588	CbGeAlD
Phylloquinone—Atrophy—Hydroxyurea—psoriasis	0.0169	0.0288	CcSEcCtD
Phylloquinone—Inflammation—Tazarotene—psoriasis	0.0151	0.0257	CcSEcCtD
Phylloquinone—Atrophy—Mycophenolic acid—psoriasis	0.0142	0.0241	CcSEcCtD
Phylloquinone—Swelling—Tazarotene—psoriasis	0.0121	0.0205	CcSEcCtD
Phylloquinone—Atrophy—Cyclosporine—psoriasis	0.0115	0.0195	CcSEcCtD
Phylloquinone—Atrophy—Mycophenolate mofetil—psoriasis	0.0112	0.019	CcSEcCtD
Phylloquinone—Atrophy—Prednisolone—psoriasis	0.0104	0.0177	CcSEcCtD
Phylloquinone—Atrophy—Hydrocortisone—psoriasis	0.0102	0.0173	CcSEcCtD
Phylloquinone—Cyanosis—Acitretin—psoriasis	0.00992	0.0169	CcSEcCtD
Phylloquinone—Atrophy—Triamcinolone—psoriasis	0.00959	0.0163	CcSEcCtD
Phylloquinone—Swelling—Fluocinonide—psoriasis	0.00923	0.0157	CcSEcCtD
Phylloquinone—Inflammation—Methoxsalen—psoriasis	0.00913	0.0155	CcSEcCtD
Phylloquinone—Atrophy—Betamethasone—psoriasis	0.0087	0.0148	CcSEcCtD
Phylloquinone—Atrophy—Dexamethasone—psoriasis	0.0087	0.0148	CcSEcCtD
Phylloquinone—Erythema—Calcipotriol—psoriasis	0.0087	0.0148	CcSEcCtD
Phylloquinone—Atrophy—Prednisone—psoriasis	0.00758	0.0129	CcSEcCtD
Phylloquinone—Erythema—Tazarotene—psoriasis	0.00641	0.0109	CcSEcCtD
Phylloquinone—Pain—Calcipotriol—psoriasis	0.00607	0.0103	CcSEcCtD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—IL13—psoriasis	0.00574	0.0641	CbGpPWpGaD
Phylloquinone—Erythema—Clobetasol propionate—psoriasis	0.00544	0.00924	CcSEcCtD
Phylloquinone—Hypersensitivity—Calcipotriol—psoriasis	0.00523	0.00889	CcSEcCtD
Phylloquinone—Cyanosis—Mycophenolate mofetil—psoriasis	0.00515	0.00875	CcSEcCtD
Phylloquinone—Immune system disorder—Fluocinonide—psoriasis	0.00509	0.00865	CcSEcCtD
Phylloquinone—Hyperbilirubinaemia—Mycophenolic acid—psoriasis	0.00508	0.00863	CcSEcCtD
Phylloquinone—Erythema—Fluocinonide—psoriasis	0.0049	0.00834	CcSEcCtD
Phylloquinone—BGLAP—Interleukin-11 Signaling Pathway—ICAM1—psoriasis	0.00456	0.051	CbGpPWpGaD
Phylloquinone—Pain—Tazarotene—psoriasis	0.00448	0.00761	CcSEcCtD
Phylloquinone—Sweating increased—Acitretin—psoriasis	0.00429	0.0073	CcSEcCtD
Phylloquinone—Necrosis—Hydrocortisone—psoriasis	0.00423	0.00719	CcSEcCtD
Phylloquinone—Hyperbilirubinaemia—Cyclosporine—psoriasis	0.00411	0.00698	CcSEcCtD
Phylloquinone—Anaphylactic shock—Beclomethasone—psoriasis	0.00404	0.00687	CcSEcCtD
Phylloquinone—Hyperbilirubinaemia—Mycophenolate mofetil—psoriasis	0.00401	0.00681	CcSEcCtD
Phylloquinone—Phlebitis—Mycophenolic acid—psoriasis	0.00389	0.00661	CcSEcCtD
Phylloquinone—Erythema—Methoxsalen—psoriasis	0.00387	0.00658	CcSEcCtD
Phylloquinone—Swelling—Mycophenolic acid—psoriasis	0.0038	0.00646	CcSEcCtD
Phylloquinone—Pain—Clobetasol propionate—psoriasis	0.00379	0.00645	CcSEcCtD
Phylloquinone—BGLAP—Validated transcriptional targets of AP1 family members Fra1 and Fra2—CXCL8—psoriasis	0.00371	0.0415	CbGpPWpGaD
Phylloquinone—BGLAP—Interleukin-11 Signaling Pathway—TYK2—psoriasis	0.00371	0.0415	CbGpPWpGaD
Phylloquinone—Injection site reaction—Mycophenolate mofetil—psoriasis	0.00362	0.00616	CcSEcCtD
Phylloquinone—Necrosis—Betamethasone—psoriasis	0.00361	0.00614	CcSEcCtD
Phylloquinone—Necrosis—Dexamethasone—psoriasis	0.00361	0.00614	CcSEcCtD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—IL4—psoriasis	0.00349	0.039	CbGpPWpGaD
Phylloquinone—Pain—Beclomethasone—psoriasis	0.00345	0.00587	CcSEcCtD
Phylloquinone—Erythema—Calcitriol—psoriasis	0.00345	0.00587	CcSEcCtD
Phylloquinone—BGLAP—Validated transcriptional targets of AP1 family members Fra1 and Fra2—JUN—psoriasis	0.00345	0.0385	CbGpPWpGaD
Phylloquinone—Pain—Fluocinonide—psoriasis	0.00342	0.00582	CcSEcCtD
Phylloquinone—Inflammation—Hydrocortisone—psoriasis	0.00342	0.00582	CcSEcCtD
Phylloquinone—Flushing—Acitretin—psoriasis	0.00327	0.00556	CcSEcCtD
Phylloquinone—Hypersensitivity—Clobetasol propionate—psoriasis	0.00327	0.00556	CcSEcCtD
Phylloquinone—Immune system disorder—Acitretin—psoriasis	0.00318	0.00541	CcSEcCtD
Phylloquinone—BGLAP—Notch-mediated HES/HEY network—CD4—psoriasis	0.00318	0.0356	CbGpPWpGaD
Phylloquinone—Necrosis—Prednisone—psoriasis	0.00315	0.00535	CcSEcCtD
Phylloquinone—Phlebitis—Mycophenolate mofetil—psoriasis	0.00307	0.00522	CcSEcCtD
Phylloquinone—Erythema—Acitretin—psoriasis	0.00307	0.00522	CcSEcCtD
Phylloquinone—Erythema—Fluocinolone Acetonide—psoriasis	0.00306	0.0052	CcSEcCtD
Phylloquinone—BGLAP—Regulation of retinoblastoma protein—PPARG—psoriasis	0.00306	0.0342	CbGpPWpGaD
Phylloquinone—Hypotension—Methoxsalen—psoriasis	0.00295	0.00502	CcSEcCtD
Phylloquinone—Hypersensitivity—Fluocinonide—psoriasis	0.00295	0.00501	CcSEcCtD
Phylloquinone—Cyanosis—Methotrexate—psoriasis	0.00292	0.00496	CcSEcCtD
Phylloquinone—Anaphylactic shock—Calcitriol—psoriasis	0.00282	0.00479	CcSEcCtD
Phylloquinone—Anaphylactoid reaction—Cyclosporine—psoriasis	0.0028	0.00476	CcSEcCtD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—ICAM1—psoriasis	0.00277	0.031	CbGpPWpGaD
Phylloquinone—Dizziness—Beclomethasone—psoriasis	0.00267	0.00454	CcSEcCtD
Phylloquinone—Dizziness—Fluocinonide—psoriasis	0.00265	0.0045	CcSEcCtD
Phylloquinone—Necrosis—Methotrexate—psoriasis	0.00263	0.00447	CcSEcCtD
Phylloquinone—BGLAP—Interleukin-11 Signaling Pathway—STAT3—psoriasis	0.0026	0.029	CbGpPWpGaD
Phylloquinone—Anaphylactoid reaction—Prednisolone—psoriasis	0.00255	0.00433	CcSEcCtD
Phylloquinone—BGLAP—FGF signaling pathway—JUN—psoriasis	0.00255	0.0285	CbGpPWpGaD
Phylloquinone—Anaphylactoid reaction—Hydrocortisone—psoriasis	0.00249	0.00423	CcSEcCtD
Phylloquinone—Sweating—Mycophenolic acid—psoriasis	0.00248	0.00421	CcSEcCtD
Phylloquinone—BGLAP—Notch-mediated HES/HEY network—STAT3—psoriasis	0.00246	0.0275	CbGpPWpGaD
Phylloquinone—Hyperhidrosis—Acitretin—psoriasis	0.00242	0.00412	CcSEcCtD
Phylloquinone—Erythema—Hydroxyurea—psoriasis	0.00241	0.0041	CcSEcCtD
Phylloquinone—Pain—Calcitriol—psoriasis	0.00241	0.00409	CcSEcCtD
Phylloquinone—Anaphylactoid reaction—Triamcinolone—psoriasis	0.00234	0.00399	CcSEcCtD
Phylloquinone—Hypersensitivity—Methoxsalen—psoriasis	0.00233	0.00396	CcSEcCtD
Phylloquinone—Sweating increased—Cyclosporine—psoriasis	0.00228	0.00388	CcSEcCtD
Phylloquinone—Hyperbilirubinaemia—Methotrexate—psoriasis	0.00227	0.00386	CcSEcCtD
Phylloquinone—BGLAP—FGF signaling pathway—STAT3—psoriasis	0.0022	0.0246	CbGpPWpGaD
Phylloquinone—BGLAP—Regulation of retinoblastoma protein—JUN—psoriasis	0.00217	0.0243	CbGpPWpGaD
Phylloquinone—Pain—Acitretin—psoriasis	0.00214	0.00364	CcSEcCtD
Phylloquinone—Pain—Fluocinolone Acetonide—psoriasis	0.00214	0.00363	CcSEcCtD
Phylloquinone—Inflammation—Methotrexate—psoriasis	0.00213	0.00362	CcSEcCtD
Phylloquinone—Anaphylactoid reaction—Betamethasone—psoriasis	0.00213	0.00362	CcSEcCtD
Phylloquinone—Anaphylactoid reaction—Dexamethasone—psoriasis	0.00213	0.00362	CcSEcCtD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—IFNG—psoriasis	0.00211	0.0236	CbGpPWpGaD
Phylloquinone—Dizziness—Methoxsalen—psoriasis	0.00209	0.00355	CcSEcCtD
Phylloquinone—BGLAP—Validated transcriptional targets of AP1 family members Fra1 and Fra2—IL6—psoriasis	0.00208	0.0233	CbGpPWpGaD
Phylloquinone—Sweating increased—Prednisolone—psoriasis	0.00208	0.00353	CcSEcCtD
Phylloquinone—Hypersensitivity—Calcitriol—psoriasis	0.00207	0.00353	CcSEcCtD
Phylloquinone—Sweating increased—Hydrocortisone—psoriasis	0.00203	0.00345	CcSEcCtD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—CXCL8—psoriasis	0.00196	0.0219	CbGpPWpGaD
Phylloquinone—Sweating—Mycophenolate mofetil—psoriasis	0.00195	0.00332	CcSEcCtD
Phylloquinone—Sweating increased—Triamcinolone—psoriasis	0.00191	0.00325	CcSEcCtD
Phylloquinone—Hypersensitivity—Acitretin—psoriasis	0.00185	0.00314	CcSEcCtD
Phylloquinone—Hypersensitivity—Fluocinolone Acetonide—psoriasis	0.00184	0.00313	CcSEcCtD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—JUN—psoriasis	0.00182	0.0204	CbGpPWpGaD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—NFKB1—psoriasis	0.00176	0.0196	CbGpPWpGaD
Phylloquinone—Dyspnoea—Hydroxyurea—psoriasis	0.00175	0.00298	CcSEcCtD
Phylloquinone—Flushing—Cyclosporine—psoriasis	0.00174	0.00296	CcSEcCtD
Phylloquinone—Sweating increased—Dexamethasone—psoriasis	0.00173	0.00295	CcSEcCtD
Phylloquinone—Sweating increased—Betamethasone—psoriasis	0.00173	0.00295	CcSEcCtD
Phylloquinone—Pain—Hydroxyurea—psoriasis	0.00168	0.00286	CcSEcCtD
Phylloquinone—Dizziness—Acitretin—psoriasis	0.00166	0.00282	CcSEcCtD
Phylloquinone—Dizziness—Fluocinolone Acetonide—psoriasis	0.00165	0.00281	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—REN—psoriasis	0.0016	0.0179	CbGpPWpGaD
Phylloquinone—Hyperhidrosis—Mycophenolic acid—psoriasis	0.00159	0.00271	CcSEcCtD
Phylloquinone—Anaphylactoid reaction—Methotrexate—psoriasis	0.00155	0.00263	CcSEcCtD
Phylloquinone—Hypotension—Mycophenolic acid—psoriasis	0.00154	0.00262	CcSEcCtD
Phylloquinone—Sweating increased—Prednisone—psoriasis	0.00151	0.00257	CcSEcCtD
Phylloquinone—Immune system disorder—Hydrocortisone—psoriasis	0.00151	0.00256	CcSEcCtD
Phylloquinone—Erythema—Prednisolone—psoriasis	0.00149	0.00253	CcSEcCtD
Phylloquinone—Dyspnoea—Mycophenolic acid—psoriasis	0.00147	0.0025	CcSEcCtD
Phylloquinone—Erythema—Hydrocortisone—psoriasis	0.00145	0.00247	CcSEcCtD
Phylloquinone—Hypersensitivity—Hydroxyurea—psoriasis	0.00145	0.00246	CcSEcCtD
Phylloquinone—Pain—Mycophenolic acid—psoriasis	0.00141	0.00239	CcSEcCtD
Phylloquinone—Erythema—Triamcinolone—psoriasis	0.00137	0.00232	CcSEcCtD
Phylloquinone—Anaphylactic shock—Cyclosporine—psoriasis	0.00133	0.00227	CcSEcCtD
Phylloquinone—Dizziness—Hydroxyurea—psoriasis	0.0013	0.00221	CcSEcCtD
Phylloquinone—Anaphylactic shock—Mycophenolate mofetil—psoriasis	0.0013	0.00221	CcSEcCtD
Phylloquinone—Hyperhidrosis—Cyclosporine—psoriasis	0.00129	0.00219	CcSEcCtD
Phylloquinone—Hyperhidrosis—Mycophenolate mofetil—psoriasis	0.00126	0.00214	CcSEcCtD
Phylloquinone—Erythema—Dexamethasone—psoriasis	0.00124	0.00211	CcSEcCtD
Phylloquinone—Erythema—Betamethasone—psoriasis	0.00124	0.00211	CcSEcCtD
Phylloquinone—Hypotension—Mycophenolate mofetil—psoriasis	0.00121	0.00207	CcSEcCtD
Phylloquinone—Anaphylactic shock—Prednisolone—psoriasis	0.00121	0.00206	CcSEcCtD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—TP53—psoriasis	0.0012	0.0135	CbGpPWpGaD
Phylloquinone—Dyspnoea—Cyclosporine—psoriasis	0.00119	0.00202	CcSEcCtD
Phylloquinone—Anaphylactic shock—Hydrocortisone—psoriasis	0.00118	0.00201	CcSEcCtD
Phylloquinone—Hyperhidrosis—Prednisolone—psoriasis	0.00117	0.00199	CcSEcCtD
Phylloquinone—Dyspnoea—Mycophenolate mofetil—psoriasis	0.00116	0.00197	CcSEcCtD
Phylloquinone—Flushing—Prednisone—psoriasis	0.00115	0.00196	CcSEcCtD
Phylloquinone—Hyperhidrosis—Hydrocortisone—psoriasis	0.00114	0.00195	CcSEcCtD
Phylloquinone—Pain—Cyclosporine—psoriasis	0.00114	0.00194	CcSEcCtD
Phylloquinone—Immune system disorder—Prednisone—psoriasis	0.00112	0.0019	CcSEcCtD
Phylloquinone—Anaphylactic shock—Triamcinolone—psoriasis	0.00112	0.0019	CcSEcCtD
Phylloquinone—Pain—Mycophenolate mofetil—psoriasis	0.00111	0.00189	CcSEcCtD
Phylloquinone—Sweating—Methotrexate—psoriasis	0.00111	0.00188	CcSEcCtD
Phylloquinone—Hypotension—Hydrocortisone—psoriasis	0.00111	0.00188	CcSEcCtD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—IL6—psoriasis	0.0011	0.0123	CbGpPWpGaD
Phylloquinone—Dizziness—Mycophenolic acid—psoriasis	0.00109	0.00185	CcSEcCtD
Phylloquinone—Erythema—Prednisone—psoriasis	0.00108	0.00184	CcSEcCtD
Phylloquinone—Hyperhidrosis—Triamcinolone—psoriasis	0.00108	0.00183	CcSEcCtD
Phylloquinone—Pain—Prednisolone—psoriasis	0.00104	0.00176	CcSEcCtD
Phylloquinone—Pain—Hydrocortisone—psoriasis	0.00101	0.00172	CcSEcCtD
Phylloquinone—Anaphylactic shock—Betamethasone—psoriasis	0.00101	0.00172	CcSEcCtD
Phylloquinone—Anaphylactic shock—Dexamethasone—psoriasis	0.00101	0.00172	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—ACE—psoriasis	0.000998	0.0112	CbGpPWpGaD
Phylloquinone—Dyspnoea—Triamcinolone—psoriasis	0.000994	0.00169	CcSEcCtD
Phylloquinone—Hypersensitivity—Cyclosporine—psoriasis	0.000982	0.00167	CcSEcCtD
Phylloquinone—Hyperhidrosis—Dexamethasone—psoriasis	0.000978	0.00166	CcSEcCtD
Phylloquinone—Hyperhidrosis—Betamethasone—psoriasis	0.000978	0.00166	CcSEcCtD
Phylloquinone—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.000958	0.00163	CcSEcCtD
Phylloquinone—Pain—Triamcinolone—psoriasis	0.000954	0.00162	CcSEcCtD
Phylloquinone—Hypotension—Dexamethasone—psoriasis	0.000945	0.00161	CcSEcCtD
Phylloquinone—Hypotension—Betamethasone—psoriasis	0.000945	0.00161	CcSEcCtD
Phylloquinone—Immune system disorder—Methotrexate—psoriasis	0.000936	0.00159	CcSEcCtD
Phylloquinone—Erythema—Methotrexate—psoriasis	0.000902	0.00153	CcSEcCtD
Phylloquinone—Hypersensitivity—Prednisolone—psoriasis	0.000893	0.00152	CcSEcCtD
Phylloquinone—Dizziness—Cyclosporine—psoriasis	0.000881	0.0015	CcSEcCtD
Phylloquinone—Anaphylactic shock—Prednisone—psoriasis	0.000881	0.0015	CcSEcCtD
Phylloquinone—Hypersensitivity—Hydrocortisone—psoriasis	0.000873	0.00148	CcSEcCtD
Phylloquinone—Pain—Dexamethasone—psoriasis	0.000865	0.00147	CcSEcCtD
Phylloquinone—Pain—Betamethasone—psoriasis	0.000865	0.00147	CcSEcCtD
Phylloquinone—Dizziness—Mycophenolate mofetil—psoriasis	0.00086	0.00146	CcSEcCtD
Phylloquinone—Hyperhidrosis—Prednisone—psoriasis	0.000852	0.00145	CcSEcCtD
Phylloquinone—Hypersensitivity—Triamcinolone—psoriasis	0.000822	0.0014	CcSEcCtD
Phylloquinone—Dizziness—Prednisolone—psoriasis	0.000802	0.00136	CcSEcCtD
Phylloquinone—Dizziness—Hydrocortisone—psoriasis	0.000783	0.00133	CcSEcCtD
Phylloquinone—Dizziness—Triamcinolone—psoriasis	0.000737	0.00125	CcSEcCtD
Phylloquinone—Anaphylactic shock—Methotrexate—psoriasis	0.000736	0.00125	CcSEcCtD
Phylloquinone—Hyperhidrosis—Methotrexate—psoriasis	0.000712	0.00121	CcSEcCtD
Phylloquinone—Hypotension—Methotrexate—psoriasis	0.000688	0.00117	CcSEcCtD
Phylloquinone—Dizziness—Betamethasone—psoriasis	0.000669	0.00114	CcSEcCtD
Phylloquinone—Dizziness—Dexamethasone—psoriasis	0.000669	0.00114	CcSEcCtD
Phylloquinone—Dyspnoea—Methotrexate—psoriasis	0.000657	0.00112	CcSEcCtD
Phylloquinone—Hypersensitivity—Prednisone—psoriasis	0.000649	0.0011	CcSEcCtD
Phylloquinone—Pain—Methotrexate—psoriasis	0.00063	0.00107	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—LEP—psoriasis	0.00062	0.00693	CbGpPWpGaD
Phylloquinone—Dizziness—Prednisone—psoriasis	0.000583	0.000991	CcSEcCtD
Phylloquinone—Hypersensitivity—Methotrexate—psoriasis	0.000543	0.000922	CcSEcCtD
Phylloquinone—Dizziness—Methotrexate—psoriasis	0.000487	0.000828	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—CXCL8—psoriasis	0.000412	0.0046	CbGpPWpGaD
